Psychotherapy
Psychedelic Therapy & Integration
I provide a safe, non-judgmental space for psychedelic integration therapy and ketamine-assisted psychotherapy for adults in Columbus, Ohio.
"It's a self treatment. It's a treatment about who I am.
These are parts of my life that happen to involve trauma... but it’s not a trauma treatment. It’s a mind-expanding treatment. We all are suffering human beings, we have all had major disappointments, we have had hurt, we have had pain in our lives, some more than others. But we’re dealing, really, with the human condition."
- Bessel van Der Kolk
Psychotherapy
Psychedelic Integration
Psychedelic integration therapy offers a safe, non-judgmental space to explore experiences with psychedelics, including IV ketamine and intranasal esketamine (Spravato), as well as psilocybin, MDMA, LSD, ayahuasca, and other substances. Our work may include preparation, making sense of difficult or meaningful experiences, and bringing insights into your relationships, choices, and daily life.
My approach is grounded in an integrative harm-reduction model: honest, practical support that meets you where you are, centers your wellbeing and autonomy, and makes room for complexity without judgment.
Integration sessions are available in person in Columbus and online throughout Ohio. I do not provide or administer substances, prescribe medication, or manage medical care. I can support you in preparing beforehand and integrating afterward, but I cannot be present during experiences involving illegal substances.
Psychotherapy
Ketamine Assisted Psychotherapy
Ketamine is a Schedule III medication that may be prescribed by an authorized clinician. In my KAP work, medical screening and prescribing are handled through a medical-prescriber partnership, while I provide preparation, supported psychotherapy, and integration. Ketamine use for mental health conditions is generally off-label. I'm currently accepting new KAP clients. Learn more about my Ketamine-Assisted Psychotherapy (KAP) services.
The current state of
Psychedelic-Assisted Psychotherapy
Psychedelic-assisted psychotherapy is an evolving area of clinical research. Psychedelic integration, by contrast, is psychotherapy that helps a person process a past experience and does not include administering a psychedelic substance.
FDA approval, clinical-trial access, state-regulated services, and local decriminalization are separate legal and regulatory pathways. Availability through a state program elsewhere does not make the same service legal in Ohio.
In Ohio, MDMA and psilocybin are Schedule I substances and are not available as routine clinical therapies outside authorized research. Ketamine is Schedule III and may be prescribed by an authorized clinician; its use for mental health treatment is generally off-label.
I intend to continue developing the education, training, and experience needed to offer additional psychedelic-assisted psychotherapy options if they become legal and are supported as safe, effective clinical tools.
Last reviewed: July 18, 2026. See the current Ohio controlled-substance schedules.
Ketamine
Ketamine is a dissociative anesthetic with established medical uses. At lower doses, it is also prescribed off-label by authorized medical professionals for some mental health conditions.
Research has examined ketamine for depression and other treatment-resistant symptoms. Individual suitability, prescribing, monitoring, and medical-risk decisions belong to the prescribing clinician. In KAP, psychotherapy can support preparation, the dosing experience, and integration afterward.
In Ohio, ketamine is a Schedule III medication. I provide psychotherapy; medical screening and prescribing are handled separately through a medical-prescriber partnership.
MDMA
MDMA, also called midomafetamine, is an entactogen being studied in combination with psychological support, especially for post-traumatic stress disorder (PTSD).
In August 2024, the FDA declined to approve Lykos Therapeutics' application and requested further study. In August 2026, industry reporting indicated that the company, now Resilient Pharmaceuticals, had quietly resubmitted the application, drawing on new safety data, third-party long-term follow-up, and an audit of the original trials. Resilient has not announced the filing, and the FDA has not issued a decision. The completed MAPP1 and MAPP2 Phase 3 studies remain part of the evidence base, but MDMA-assisted therapy is still investigational and is not FDA-approved.
In Ohio, MDMA remains Schedule I and is not available for routine therapeutic use outside authorized clinical research.
Last reviewed: August 12, 2026. Read the FDA decision summary, reporting on the resubmission, or search current MDMA trials.
Psilocybin
Psilocybin is a psychedelic compound found in certain mushrooms. It is being studied for depression and other conditions, but no psilocybin treatment is currently FDA-approved.
In 2026, Compass Pathways reported that both pivotal Phase 3 trials of investigational COMP360 psilocybin met their primary endpoints for treatment-resistant depression, followed by six-month COMP006 data. These are sponsor-reported trial results; COMP360 remains investigational while regulatory review continues.
Oregon and Colorado have separate state-regulated psilocybin programs. Those programs are not the same as FDA approval and do not create legal access in Ohio.
In Ohio, psilocybin remains Schedule I and is not available for routine therapeutic use outside authorized clinical research.
Last reviewed: July 18, 2026. Read the Phase 3 update, search current psilocybin trials, or review Ohio law.
Let's stay in touch.
Interested in working together? Please join the waitlist. I also offer group psychedelic-assisted psychotherapy programs with LuminaThera.
If you'd like occasional practice updates, including openings and new offerings, please sign up for emails. I don't send out recurring email blasts and promise to be respectful of your inbox!